Production (Stage)
Adverum Biotechnologies, Inc.
ADVM
$2.21
-$0.02-0.90%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -27.41% | -9.15% | 19.63% | 19.68% | 17.49% |
| Total Depreciation and Amortization | -33.87% | -35.28% | -39.31% | -32.52% | -24.59% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -4.36% | 2.67% | -23.81% | 27.27% | 53.10% |
| Change in Net Operating Assets | 144.51% | 125.70% | -612.80% | -297.92% | -173.77% |
| Cash from Operations | -22.08% | -1.72% | 2.85% | 7.94% | 9.69% |
| Capital Expenditure | 36.29% | 51.98% | 35.21% | 29.82% | 89.20% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -77.95% | -142.49% | -142.86% | -113.11% | -37.35% |
| Cash from Investing | -78.58% | -143.24% | -143.65% | -113.92% | -32.40% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.80% | 24,464.21% | 24,464.83% | 24,515.37% | 19,828.64% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 77.91% | 23.53% | -- |
| Cash from Financing | -99.90% | 173,817.39% | 82,610.34% | 47,830.00% | 19,759.11% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -223.20% | -337.47% | -162.56% | -20.57% | 468.91% |